Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

527
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
527
Cancer Vaccines01:30

Cancer Vaccines

936
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
936
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same author

Prognostic Factors and Survival Outcomes in Resectable Thoracic Soft Tissue and Bone Sarcomas.

Cancers·2026
Same author

Oncological Outcomes of Complete Versus Limited Thymectomy in Early Stage Thymic Epithelial Tumors: A Systematic Review and Individual Patient Data Meta-Analysis.

JTO clinical and research reports·2026
Same author

A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Cost evaluation of a multimodal prehabilitation program for high-risk lung cancer surgery.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Predictors of distant, local and lymph node recurrence for surgically treated non-small cell lung cancer (NSCLC) patients: Retrospective analysis of pathological T1-4, N0, R0, M0 tumor stages.

Pneumologie (Stuttgart, Germany)·2026

Related Experiment Video

Updated: Jan 10, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

Neoadjuvant Chemoimmunotherapy.

Gökce Yavuz1, Jonathan D Spicer1

  • 1Division of Thoracic Surgery, McGill University Health Center, 1650 Cedar Avenue, Montreal, Quebec, H3H 1V6, Canada.

Thoracic Surgery Clinics
|November 19, 2025
PubMed
Summary
This summary is machine-generated.

Neoadjuvant chemoimmunotherapy significantly improves outcomes for early-stage non-small cell lung cancer (NSCLC) by increasing pathologic complete response and event-free survival without added perioperative risks.

Keywords:
Checkpoint inhibitorsChemotherapyImmunotherapyNSCLCNeoadjuvant therapyPD-1

More Related Videos

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.9K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K

Related Experiment Videos

Last Updated: Jan 10, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.9K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Surgery

Background:

  • Neoadjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC) offers limited survival benefits.
  • Evolving treatment paradigms are exploring novel neoadjuvant strategies for early-stage NSCLC.

Purpose of the Study:

  • To evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy in early-stage resectable non-small cell lung cancer (NSCLC).
  • To assess the impact of novel neoadjuvant strategies on pathologic complete response and event-free survival.

Main Methods:

  • Analysis of recent clinical trials investigating neoadjuvant chemotherapy combined with immune checkpoint inhibitors.
  • Assessment of perioperative risks associated with combined neoadjuvant therapy.

Main Results:

  • Combining chemotherapy with immunotherapy significantly enhances pathologic complete response rates.
  • Event-free survival is improved with neoadjuvant chemoimmunotherapy.
  • Perioperative risks are not substantially increased by the addition of immunotherapy.

Conclusions:

  • Neoadjuvant chemoimmunotherapy represents a significant advancement in the multimodal management of resectable NSCLC.
  • This approach is poised to become a cornerstone of standard care for early-stage NSCLC.
  • Future research will focus on biomarker-driven personalization of neoadjuvant treatment strategies.